EU guideline revamp to clarify pediatric drug development rules
This article was originally published in Scrip
Executive Summary
The European Commission is revising its 2008 guideline on pediatric investigation plans (PIPs) to bring it more into line with actual practice. The move is expected to clarify the rules in a number of areas and is seen as an important step in encouraging more companies to pursue pediatric drug development programs.